Evidence map›Paper›PMID 35356629›Full record

ArticleFrontiers in pharmacology2021

Target Specific Inhibition of Protein Tyrosine Kinase in Conjunction With Cancer and SARS-COV-2 by Olive Nutraceuticals.

Arabinda Ghosh, Nobendu Mukerjee, Bhavdeep Sharma, Anushree Pant, Yugal Kishore Mohanta, Rahul D Jawarkar, Ravindrakumar L Bakal, Ermias Mergia Terefe, Gaber El-Saber Batiha, Gomaa Mostafa-Hedeab and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Combination ofJournal of cardiovascular development and disease · 2022
    Article
  8. COVID-19 diagnostic methods in developing countries.Environmental science and pollution research international · 2022
    Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 4 countries.

Arabinda GhoshMicrobiology Division, Department of Botany, Gauhati University, Guwahati, India.
Nobendu MukerjeeDepartment of Microbiology, Ramakrishna Mission Vivekananda Centenary College, Kolkata, India.
Bhavdeep SharmaDepartment of Biotechnology, Thapar Institute of Engineering and Technology, Patiala, India.
Anushree PantDepartment of Biotechnology, Thapar Institute of Engineering and Technology, Patiala, India.
Yugal Kishore MohantaDepartment of Applied Biology, University of Science and Technology Meghalaya, Ri Bhoi, India.
Rahul D JawarkarDepartment of Medicinal Chemistry, Dr. Rajendra Gode Institute of Pharmacy, Amravati, India.
Ravindrakumar L BakalDepartment of Medicinal Chemistry, Dr. Rajendra Gode Institute of Pharmacy, Amravati, India.
Ermias Mergia TerefeDepartment of Pharmacology and Pharmacognosy, School of Pharmacy and Health Sciences, United states International University-Africa, Nairobi, Kenya.
Gaber El-Saber BatihaDepartment of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, Egypt.
Gomaa Mostafa-HedeabPharmacology Department & Health Research Unit-Medical College-Jouf University, Sakakah, Saudi Arabia.
Nisreen Khalid Aref AlbezrahObstetrics and Gynecology Department, College of Medicine, Taif University, Taif, Saudi Arabia.
Abhijit DeyDepartment of Life Sciences, Presidency University, Kolkata, India.
Debabrat BaishyaDepartment of Bioengineering, Gauhati University, Guwahati, India.
Gauhati University · INSant Gadge Baba Amravati University · INThapar Institute of Engineering & Technology · INAl Jouf University · SADamanhour University · EGPresidency University · INRamakrishna Mission Vivekananda Educational and Research Institute · INTaif University · SAUnited States International University Africa · KEUniversity of Science and Technology, Meghalaya · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The fact that viruses cause human cancer dates back to the early 1980s. By reprogramming cellular signaling pathways, viruses encoded protein that can regulate altered control of cell cycle events. Viruses can interact with a superfamily of membrane bound protein, receptor tyrosine kinase to modulate their activity in order to increase virus entrance into cells and promotion of viral replication within the host. Therefore, our study aimed at screening of inhibitors of tyrosine kinase using natural compounds from olive. Protein tyrosine kinase (PTK) is an important factor for cancer progression and can be linked to coronavirus. It is evident that over expression of Protein tyrosine kinase (PTK) enhance viral endocytosis and proliferation and the use of tyrosine kinase inhibitors reduced the period of infection period. Functional network studies were carried out using two major PTKs viz. Anaplastic lymphoma kinase (ALK) and B-lymphocytic kinase (BTK). They are associated with coronavirus in regulation of cell signaling proteins for cellular processes. We virtually screened for 161 library of natural compounds from olive found overexpressed in ALK and BTK in metastatic as well as virus host cells. We have employed both ligand and target-based approach for drug designing by high throughput screening using Multilinear regression model based QSAR and docking. The QSAR based virtual screening of 161 olive nutraceutical compounds has successfully identified certain new hit; Wedelosin, in which, the descriptor rsa (ratio of molecular surface area to the solvent accessible surface area) plays crucial role in deciding Wedelosin's inhibitory potency. The best-docked olive nutraceuticals further investigated for the stability and effectivity of the BTK and ALK during in 150 ns molecular dynamics and simulation. Post simulation analysis and binding energy estimation in MMGBSA further revealed the intensive potential of the olive nutraceuticals in PTK inhibition. This study is therefore expected to widen the use of nutraceuticals from olive in cancer as well as SARS-CoV2 alternative therapy.

Indexed as

ALKBTKMD simulationOliveQSARSARS CoV-2Wedelosin

Identifiers

PMID35356629
PMCPMC8959131
OpenAlexW4283020691

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.